BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1099 related articles for article (PubMed ID: 31120439)

  • 1. Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation in RGS6-deficient mice.
    Luo Z; Ahlers-Dannen KE; Spicer MM; Yang J; Alberico S; Stevens HE; Narayanan NS; Fisher RA
    JCI Insight; 2019 May; 5(13):. PubMed ID: 31120439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RGS Proteins as Critical Regulators of Motor Function and Their Implications in Parkinson's Disease.
    Ahlers-Dannen KE; Spicer MM; Fisher RA
    Mol Pharmacol; 2020 Dec; 98(6):730-738. PubMed ID: 32015009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
    Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased vulnerability of nigral dopamine neurons after expansion of their axonal arborization size through D2 dopamine receptor conditional knockout.
    Giguère N; Delignat-Lavaud B; Herborg F; Voisin A; Li Y; Jacquemet V; Anand-Srivastava M; Gether U; Giros B; Trudeau LÉ
    PLoS Genet; 2019 Aug; 15(8):e1008352. PubMed ID: 31449520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons.
    Dragicevic E; Poetschke C; Duda J; Schlaudraff F; Lammel S; Schiemann J; Fauler M; Hetzel A; Watanabe M; Lujan R; Malenka RC; Striessnig J; Liss B
    Brain; 2014 Aug; 137(Pt 8):2287-302. PubMed ID: 24934288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The deglycase activity of DJ-1 mitigates α-synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ-1 in Parkinson's disease.
    Sharma N; Rao SP; Kalivendi SV
    Free Radic Biol Med; 2019 May; 135():28-37. PubMed ID: 30796974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
    Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
    Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine-dependent early synaptic and motor dysfunctions induced by α-synuclein in the nigrostriatal circuit.
    Tozzi A; Sciaccaluga M; Loffredo V; Megaro A; Ledonne A; Cardinale A; Federici M; Bellingacci L; Paciotti S; Ferrari E; La Rocca A; Martini A; Mercuri NB; Gardoni F; Picconi B; Ghiglieri V; De Leonibus E; Calabresi P
    Brain; 2021 Dec; 144(11):3477-3491. PubMed ID: 34297092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Parkinson's patient-derived dopamine neurons, the triplication of α-synuclein locus induces distinctive firing pattern by impeding D2 receptor autoinhibition.
    Lin M; Mackie PM; Shaerzadeh F; Gamble-George J; Miller DR; Martyniuk CJ; Khoshbouei H
    Acta Neuropathol Commun; 2021 Jun; 9(1):107. PubMed ID: 34099060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AMP-activated protein kinase slows D2 dopamine autoreceptor desensitization in substantia nigra neurons.
    Yang W; Munhall AC; Johnson SW
    Neuropharmacology; 2019 Nov; 158():107705. PubMed ID: 31301335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective α-Synuclein Knockdown in Monoamine Neurons by Intranasal Oligonucleotide Delivery: Potential Therapy for Parkinson's Disease.
    Alarcón-Arís D; Recasens A; Galofré M; Carballo-Carbajal I; Zacchi N; Ruiz-Bronchal E; Pavia-Collado R; Chica R; Ferrés-Coy A; Santos M; Revilla R; Montefeltro A; Fariñas I; Artigas F; Vila M; Bortolozzi A
    Mol Ther; 2018 Feb; 26(2):550-567. PubMed ID: 29273501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations in the nigrostriatal system following conditional inactivation of α-synuclein in neurons of adult and aging mice.
    Ninkina N; Tarasova TV; Chaprov KD; Roman AY; Kukharsky MS; Kolik LG; Ovchinnikov R; Ustyugov AA; Durnev AD; Buchman VL
    Neurobiol Aging; 2020 Jul; 91():76-87. PubMed ID: 32224067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impairment of Macroautophagy in Dopamine Neurons Has Opposing Effects on Parkinsonian Pathology and Behavior.
    Hunn BHM; Vingill S; Threlfell S; Alegre-Abarrategui J; Magdelyns M; Deltheil T; Bengoa-Vergniory N; Oliver PL; Cioroch M; Doig NM; Bannerman DM; Cragg SJ; Wade-Martins R
    Cell Rep; 2019 Oct; 29(4):920-931.e7. PubMed ID: 31644913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation.
    Liu G; Yu J; Ding J; Xie C; Sun L; Rudenko I; Zheng W; Sastry N; Luo J; Rudow G; Troncoso JC; Cai H
    J Clin Invest; 2014 Jul; 124(7):3032-46. PubMed ID: 24865427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-synuclein as a pathological link between chronic traumatic brain injury and Parkinson's disease.
    Acosta SA; Tajiri N; de la Pena I; Bastawrous M; Sanberg PR; Kaneko Y; Borlongan CV
    J Cell Physiol; 2015 May; 230(5):1024-32. PubMed ID: 25251017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are Dopamine Oxidation Metabolites Involved in the Loss of Dopaminergic Neurons in the Nigrostriatal System in Parkinson's Disease?
    Herrera A; Muñoz P; Steinbusch HWM; Segura-Aguilar J
    ACS Chem Neurosci; 2017 Apr; 8(4):702-711. PubMed ID: 28233992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of dopaminergic neuron loss in Parkinson's disease.
    Surmeier DJ
    FEBS J; 2018 Oct; 285(19):3657-3668. PubMed ID: 30028088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron, Dopamine, and α-Synuclein Interactions in at-Risk Dopaminergic Neurons in Parkinson's Disease.
    Song N; Xie J
    Neurosci Bull; 2018 Apr; 34(2):382-384. PubMed ID: 29380248
    [No Abstract]   [Full Text] [Related]  

  • 19. Up-regulation of activating transcription factor 4 induces severe loss of dopamine nigral neurons in a rat model of Parkinson's disease.
    Gully JC; Sergeyev VG; Bhootada Y; Mendez-Gomez H; Meyers CA; Zolotukhin S; Gorbatyuk MS; Gorbatyuk OS
    Neurosci Lett; 2016 Aug; 627():36-41. PubMed ID: 27233218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Midbrain Gene Screening Identifies a New Mesoaccumbal Glutamatergic Pathway and a Marker for Dopamine Cells Neuroprotected in Parkinson's Disease.
    Viereckel T; Dumas S; Smith-Anttila CJ; Vlcek B; Bimpisidis Z; Lagerström MC; Konradsson-Geuken Å; Wallén-Mackenzie Å
    Sci Rep; 2016 Oct; 6():35203. PubMed ID: 27762319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.